Stacie Weninger is the President of FBRI, which was created to advance research in Alzheimer’s disease and related brain disorders. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards. Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Aratome, Digital Cognition Technologies, and Target ALS; and she previously served as a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI) as well as a member of the Board of Directors for Annexon Biosciences, BRI-Alzan (acquired by MeiraGTx), Enspectra, Inscopix, and Q-State Biosciences. Join us for lunch with Stacie to learn more about her career path.